The Clinical Importance of the Heterogeneity of HER2 neu

被引：11

作者：

Davila, Enrique ^{[1
]}

Amazon, Kip ^{[2
]}

机构：

[1] Aventura Hosp & Med Ctr, Aventura Comprehens Canc Ctr, Aventura, FL USA

[2] Aventura Hosp & Med Ctr, Dept Pathol, Aventura, FL USA

来源：

CASE REPORTS IN ONCOLOGY | 2010年 / 3卷 / 02期

关键词：

HER2; neu; Herceptin; Trastuzumab; Breast cancer; Treatment;

D O I：

10.1159/000319020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We report on a patient with breast cancer in whom there were areas of the tumor that were 3+ positive and negative for HER2 neu by immunohistochemistry, adjacent to each other. Depending on the area tested the results were completely different. The clinical implications are important. We recommend retesting a large portion of the tumor in all cases of initially negative test results.

引用

页码：268 / 271

页数：4

共 10 条

[1]

[Anonymous], 2010, MS171201009182 NCCN, V1

[2] Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study [J].

Burstein, HJ ;

Harris, LN ;

Gelman, R ;

Lester, SC ;

Nunes, RA ;

Kaelin, CM ;

Parker, LM ;

Ellisen, LW ;

Kuter, I ;

Gadd, MA ;

Christian, RL ;

Kennedy, PR ;

Borges, VF ;

Bunnell, CA ;

Younger, J ;

Smith, BL ;

Winer, EP .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :46-53

[3]

Dubey S, 2004, J CLIN ONCOL, V22, p856S

[4] Marked intratumoral heterogeneity of c-myc and CyclinD1 but not of c-erbB2 amplification in breast cancer [J].

Glöckner, S ;

Buurman, H ;

Kleeberger, W ;

Lehmann, U ;

Kreipe, H .

LABORATORY INVESTIGATION, 2002, 82 (10) :1419-1426

[5] Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice [J].

Hudis, Clifford A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (01) :39-51

[6] Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining [J].

Lewis, JT ;

Ketterling, RP ;

Halling, KC ;

Reynolds, C ;

Jenkins, RB ;

Visscher, DW .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2005, 124 (02) :273-281

[7] Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer [J].

Paik, Soonmyung ;

Tang, Gong ;

Shak, Steven ;

Kim, Chungyeul ;

Baker, Joffre ;

Kim, Wanseop ;

Cronin, Maureen ;

Baehner, Frederick L. ;

Watson, Drew ;

Bryant, John ;

Costantino, Joseph P. ;

Geyer, Charles E., Jr. ;

Wickerham, D. Lawrence ;

Wolmark, Norman .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (23) :3726-3734

[8] HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial [J].

Perez, Edith A. ;

Suman, Vera J. ;

Davidson, Nancy E. ;

Martino, Silvana ;

Kaufman, Peter A. ;

Lingle, Wilma L. ;

Flynn, Patrick J. ;

Ingle, James N. ;

Visscher, Daniel ;

Jenkins, Robert B. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) :3032-3038

[9]

Vance GH, 2009, ARCH PATHOL LAB MED, V133, P611, DOI 10.1043/1543-2165-133.4.611

[10] American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer [J].

Wolff, Antonio C. ;

Hammond, M. Elizabeth H. ;

Schwartz, Jared N. ;

Hagerty, Karen L. ;

Allred, D. Craig ;

Cote, Richard J. ;

Dowsett, Mitchell ;

Fitzgibbons, Patrick L. ;

Hanna, Wedad M. ;

Langer, Amy ;

McShane, Lisa M. ;

Paik, Soonmyung ;

Pegram, Mark D. ;

Perez, Edith A. ;

Press, Michael F. ;

Rhodes, Anthony ;

Sturgeon, Catharine ;

Taube, Sheila E. ;

Tubbs, Raymond ;

Vance, Gail H. ;

de Vijver, Marc Van ;

Wheeler, Thomas M. ;

Hayes, Daniel F. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (01) :118-145

← 1 →